The proteasome pathway in the CIS clinical subtype (including both MSs-CIS and SA-MS) has been over activated with the increase expression of PSMB10, PSMA2, PSMA1, PSMD13, PSMB2, PSME3 proteins. This evidence concerns the gene PSME3 and in situ carcinoma.